The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...
Epcoritamab combined with R-mini-CHOP or R-CHOP shows high ORR and CR rates in newly diagnosed DLBCL patients, including high-risk and older populations. The trial achieved significant MRD negativity, ...
Thomas M. Habermann, MD, is a hematologist with the Mayo Clinic in Rochester, Minnesota. A member of the Lymphoma Research Foundation Scientific Advisory Board, Habermann is well known as the lead ...
Incyte said on Monday its experimental combo therapy helped patients live longer without their disease worsening in a late-stage study of a type of blood cancer, sending its shares up about 3% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback